Browse the corpus

Exacerbations requiring oral systemic corticosteroids 0-1/year 2-3/year >3/year Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with persistent asthma. EIB: exercise-induced bronchospasm; ICU: intensive care unit. Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007. Assessing asthma control in children 5-11 years of age Components of control Classification of asthma control (children 5-11 years of age) Well-controlled Not-well controlled Very poorly controlled Impairment Symptoms ≤2 days/week but not more than once on each day >2 days/week or multiple times on ≤2 days/week Throughout the day Nighttime awakenings ≤1x/month ≥2x/month ≥2x/week Interference with normal activity None Some limitation Extremely limited Short-acting beta 2 -agonist use for symptom control (not prevention of EIB) ≤2 days/week >2 days/week Several times per day Lung function FEV 1 or peak flow >80 percent predicted/personal best 60-80 percent predicted/personal best <60 percent predicted/personal best FEV 1 /FVC >80 percent 75-80 percent <75 percent Risk

Consider severity and interval since last exacerbation Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's/caregiver's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma. EIB: exercise-induced bronchospasm; FEV 1 : forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit. Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007. Assessing asthma control in youths greater than or equal to 12 years of age and adults Components of control Classification of asthma control (youths ≥12 years of age and adults) Well-controlled Not-well controlled Very poorly controlled Impairment Symptoms ≤2 days/week >2 days/week Throughout the day Nighttime awakenings ≤2x/month 1-3x/week ≥4x/week Interference with normal activity None Some limitation Extremely limited Short-acting beta 2 -agonist use for symptom control (not prevention of EIB) ≤2 days/week >2 days/week Several times per day FEV 1 or peak flow >80 percent predicted/personal best 60-80 percent predicted/personal best <60 percent predicted/personal best Validated questionnaires ATAQ 0 1-2 3-4 ACQ ≤0.75* ≥1.5 N/A ACT ≥20 16-19 ≤15 Risk

Consider severity and interval since last exacerbation Progressive loss of lung function Evaluation requires long-term followup care Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma. EIB: exercise-induced bronchospasm; FEV 1 : forced expiratory volume in 1 second; ATAQ: Asthma Therapy Assessment Questionnaire (Vollmer et al. 1999); ACQ: Asthma Control Questionnaire (Juniper et al. 1999b); ACT: Asthma Control Test (Nathan et al. 2004); N/A: not applicable. * ACQ values of 0.76-1.4 are indeterminate regarding well-controlled asthma. Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.

Exacerbations requiring oral systemic corticosteroids 0-1/year 2-3/year >3/year Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. The level of control is based on the most severe impairment or risk category. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with persistent asthma. EIB: exercise-induced bronchospasm; ICU: intensive care unit. Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.